EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study

Andreas A Argyriou, Jordi Bruna iD, Foteini Kalofonou, Roser Velasco, Pantelis Litsardopoulos, Montse Alemany, Garifallia G Anastopoulou, Haralabos P Kalofonos iD

Journal of the Peripheral Nervous System · 2024-03 · 29 (1) · 38-46

DOI: 10.1111/jns.12616 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 04.02.2024. Verfasst von Andreas A Argyriou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Department, "Agios Andreas" General Hospital of Patras, Patras, Greece. Hauptthemen laut MEDLINE: Neuralgia, Neoplasms, Neurotoxicity Syndromes, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Instituto de Salud Carlos III (ISCIII), European Regional Development FUND-ERDF, Spanish Foundation Research Group in Breast Cancer (GEICAM).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP).

Methods

Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy‐induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI‐NRS and Douleur Neuropathique‐4 questionnaire. The total neuropathy score‐clinical version graded the severity of CIPN.

Results

The medical files of 500 chemotherapy‐treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2–3 chronic CIPN (OR: 1.61; p < .001) as also the administration of combined paclitaxel plus cisplatin (reference variable), compared to oxaliplatin (OR: 0.18; p = .001) and taxanes (OR: 0.16; p < .001). The increased severity of acute OXAIPN was associated with CINP (OR: 4.51; p < .001). OXA‐treated patients with persistent CINP presented a worst likelihood to improve after chemotherapy discontinuation, than patients receiving combined paclitaxel plus cisplatin (OR: 50; p < .001).

Conclusion

The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post‐chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA‐treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaNeoplasmsNeurotoxicity SyndromesAntineoplastic AgentsDiabetes MellitusHumansCisplatinOxaliplatinIncidenceRetrospective StudiesPaclitaxelRisk Factors

Stichwörter der Autor:innen

chemotherapy-induced neuropathic painchemotherapy-induced peripheral neurotoxicityincidencepredictionseverity

Substanzen

CisplatinOxaliplatinPaclitaxelAntineoplastic Agents

Autor:innen und Institutionen

  • Neurological Department, "Agios Andreas" General Hospital of Patras, Patras, Greece.
  • Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO L'Hospitalet, IDIBELL, Barcelona, Spain.
  • Department of Oncology, Guy's and St. Thomas' NHS Trust, London, UK.
  • Department of Medicine, "Agios Andreas" General Hospital of Patras, Patras, Greece.
  • Department of Medicine, Division of Oncology, University Hospital of Patras, Patras, Greece.

ORCID-Profile: Jordi Bruna, Haralabos P Kalofonos

Förderung

  • Instituto de Salud Carlos III (ISCIII)
  • European Regional Development FUND-ERDF
  • Spanish Foundation Research Group in Breast Cancer (GEICAM)

Zitieren

APA

Argyriou, A. A., Bruna, J., Kalofonou, F., Velasco, R., Litsardopoulos, P., Alemany, M., Anastopoulou, G. G., & Kalofonos, H. P. (2024). Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study. Journal of the Peripheral Nervous System, 29(1), 38-46. https://doi.org/10.1111/jns.12616

Vancouver

Argyriou AA, Bruna J, Kalofonou F, Velasco R, Litsardopoulos P, Alemany M, et al. Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study. Journal of the Peripheral Nervous System. 2024;29(1):38-46. doi:10.1111/jns.12616

BibTeX
@article{Argyriou2024,
  author = {Argyriou, Andreas A and Bruna, Jordi and Kalofonou, Foteini and Velasco, Roser and Litsardopoulos, Pantelis and Alemany, Montse and Anastopoulou, Garifallia G and Kalofonos, Haralabos P},
  title = {Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  volume = {29},
  number = {1},
  pages = {38--46},
  doi = {10.1111/jns.12616}
}
Kostenlos starten →